Ioflupane (123i) Rotop (Ioflupane (123i))

Ioflupane I-123 selectively binds to presynaptic dopamine transporters in the brain. The iodine‑123 label emits gamma radiation that is captured by SPECT cameras, producing detailed images that reflect the density of functional dopamine transporters.

The administered dose of Ioflupane (123i) Rotop is determined by the prescribing physician or nuclear medicine specialist based on patient characteristics, imaging protocol, and regulatory guidelines. Exact dosing is not standardized in public literature.

Safety data for Ioflupane (123i) Rotop in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks, and clinicians should discuss individual circumstances with the patient.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ioflupane I-123 is a widely used SPECT tracer offering high specificity for dopamine transporters. Compared with alternatives such as ^99mTc‑TRODAT‑1, Ioflupane provides superior image resolution and longer half‑life, facilitating broader clinical use, though choice depends on local regulatory approval and imaging infrastructure.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Use aseptic technique for preparation and administer promptly after removal from refrigeration to maintain radiochemical stability.

Ioflupane (123i) Rotop is administered as an intravenous injection by a qualified healthcare professional. After injection, a waiting period of approximately 3–6 hours is typical before SPECT imaging to allow optimal brain uptake and clearance of background activity.

Serious risks include rare allergic reactions such as anaphylaxis, severe hypotension, and potential radiation‑induced thyroid dysfunction. Patients should be monitored for immediate hypersensitivity signs and evaluated for thyroid health, especially if they have pre‑existing thyroid disease.

Ioflupane (123i) Rotop should be avoided in patients with known hypersensitivity to iodine‑123 compounds, those who have received recent iodine‑containing contrast agents, and individuals where the diagnostic benefit does not outweigh the radiation exposure, such as certain pregnant or lactating patients.